News Archives | Page 5 of 8

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

Proceeds to advance clinical development of WU-NK-101 for relapsed/refractory AML, and initiate studies in solid tumor indications. Oversubscribed Series B co-led by Abingworth and Tybourne Capital Management, and joined by…

15 July

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL),

American Society of Hematology Annual Meeting, Ghobadi et al, December 2023

13 December

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

Science Translational Medicine, Berrien-Elliot et al, February 2022

25 February

Cell-based immunotherapy shows promise against melanoma

Source: SITEMAN Cancer Center, Julia Evangelou Strait, June 2021.

01 July

Memory-like differentiation enhances NK cell responses to melanoma

Clin Cancer Res, Marin et al, June 2021

30 June

Wugen: deploying memory NK cells against cancer

Source: BIOCENTURY Wugen: deploying memory NK cells against cancer AND TURNING ALLOGENEIC CAR T CELLS AGAINST T CELL MALIGNANCIES BY LAUREN MARTZ, SENIOR EDITOR MAY 17, 2021 | 2:08 PM…

17 May

Wugen Appoints Daniel Kemp, Ph.D., as Chief Executive Officer

Biotech Executive and former Vice President of Research & Development at Takeda Pharmaceuticals brings notable expertise in cell therapies and strategic business development to the companyST. LOUIS, MO, and SAN…

14 April

The Development of Natural Killer Cells for Solid Tumor Treatment

Currently approved cellular therapies have been shown to effectively treat B-cell cancers, but there remains a significant unmet need for treating other cancers, including solid tumors.

26 March

BioWorld: Alpha Biopharma lands deal for Wugen’s memory NK and CAR T cells for Asia

BioWorld, David Ho, March 2021.

13 March

Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer

ST. LOUIS, MO, March 8, 2021 /PRNewswire/ – Wugen Inc., a clinical-stage biotechnology company developing novel universal natural killer (NK) and T-cell therapies for the treatment of cancer, today announced…

08 March

ARCHIVE

Wugen Raises $172 Million to Advance Clinical Stage Memory NK Cell Platform, Progress Best-In-Class AML Program, and Initiate Multiple Solid Tumor Trials

Phase 1/2 Dose-Escalation/Dose-Expansion Study of Anti-CD7 Allogeneic CAR-T Cells (WU-CART-007) in Relapsed or Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia/ Lymphoblastic Lymphoma (T-ALL/LBL),

Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia

Cell-based immunotherapy shows promise against melanoma

Memory-like differentiation enhances NK cell responses to melanoma

Wugen: deploying memory NK cells against cancer

Wugen Appoints Daniel Kemp, Ph.D., as Chief Executive Officer

The Development of Natural Killer Cells for Solid Tumor Treatment

BioWorld: Alpha Biopharma lands deal for Wugen’s memory NK and CAR T cells for Asia

Wugen Announces Exclusive Partnership Agreement With Alpha Biopharma in Asia For Cell Therapies to Treat Cancer

ST. LOUIS

SOCIAL